144 related articles for article (PubMed ID: 31010323)
1. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.
Abogunrin S; Ashaye AO; Cappelleri JC; Clair AG; Fahrbach K; Ramaswamy K; Serfass L; Srinivas S; Thomaidou D; Zanotti G
Future Oncol; 2019 Jun; 15(18):2175-2190. PubMed ID: 31010323
[TBL] [Abstract][Full Text] [Related]
2. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
[TBL] [Abstract][Full Text] [Related]
3. Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma.
Ishiyama R; Ishihara H; Kondo T; Takagi T; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
In Vivo; 2019; 33(6):2153-2160. PubMed ID: 31662551
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.
Cheng W; Kletas V; Kollmannsberger C; de Lemos M
J Oncol Pharm Pract; 2020 Jan; 26(1):67-73. PubMed ID: 30909792
[TBL] [Abstract][Full Text] [Related]
5. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
[TBL] [Abstract][Full Text] [Related]
6. Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment.
Czarnecka AM
Nat Rev Urol; 2017 May; 14(5):264-266. PubMed ID: 28266515
[No Abstract] [Full Text] [Related]
7. The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis.
Sun Y; Li J; Yang X; Zhang G; Fan X
Clin Genitourin Cancer; 2019 Oct; 17(5):e847-e859. PubMed ID: 31279483
[TBL] [Abstract][Full Text] [Related]
8. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
Gyawali B; Goldstein DA
JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
[No Abstract] [Full Text] [Related]
9. Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis.
Chen C; Fang H; Jiao Y; Zhou Y; Guo Q; Lv Z
Clin Genitourin Cancer; 2019 Oct; 17(5):319-331. PubMed ID: 31371223
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
11. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
12. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
13. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsukav A
Med Oncol; 2018 Aug; 35(10):133. PubMed ID: 30128854
[TBL] [Abstract][Full Text] [Related]
14. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
15. Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.
Wood SY; Ryan JC; Clair AG; George DJ
Future Oncol; 2020 Feb; 16(4):39-47. PubMed ID: 31922424
[TBL] [Abstract][Full Text] [Related]
16. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA; Heng DYC; Macfarlane RJ; Venner PM; Kapoor A; Hansen AR; Eigl BJ; Czaykowski P; Boyd B; Wang L; Basappa NS
Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632
[TBL] [Abstract][Full Text] [Related]
18. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
19. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
